Looking for the Next "PSA"
Executive Summary
Cancer diagnostics has been a tough field for companies. But the need for good tests remains, and with new technologies being discovered, the opportunities still seem worth pursuing. Witness the deals signed in the field in the past half year. While none are large, they address either diagnostic companies' search for growth and high value, proprietary tests, or biotech companies' desire to foster basic research for pharmaceutical products or evaluate therapeutic impact on specific patients.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.